Steinauer Laura M, Leung Jonathan G, Burkey Betsy Walters, McGrane Ian R, Letts Victoria, Goren Jessica L, Hoeft Dawn M, Mullen Sandra, Maroney Megan, Schak Kathryn M, Vande Voort Jennifer L
1 Department of Pharmacy, Mayo Clinic , Rochester, Minnesota.
2 Department of Pharmacy, Fairview Hospital/Cleveland Clinic Children's Hospital , Cleveland, Ohio.
J Child Adolesc Psychopharmacol. 2018 Nov;28(9):615-619. doi: 10.1089/cap.2018.0036. Epub 2018 Oct 24.
Clozapine is the drug of choice for treatment-resistant schizophrenia. While pediatric clozapine use is not contraindicated, the literature describing its clinical application is limited. The primary objective of this study was to assess the use of clozapine in a child and adolescent population by characterizing the documented safety and clinical benefits of the medication.
A multicenter retrospective study at sites in the United States and Australia included children and adolescents admitted to a psychiatric unit who were administered at least one dose of clozapine. Information related to demographics, patient history, past treatments, clozapine, and adverse events was collected.
Eighty-two patients from eight sites were included in this study. Patients were predominantly clozapine naive (76.8%), and most had a discharge diagnosis of a primary psychotic disorder (61%) or bipolar disorder (25.6%). Four clozapine discontinuations occurred during hospitalization due to severe neutropenia, ileus, need for diagnostic clarification, and significant psychomotor retardation. The remainder (n = 78) were discharged on a mean clozapine dose of 218.1 ± 142.2 mg. Sedation (26.8%) and sialorrhea (17.1%) were the most common documented adverse events. The mean number of previously trialed antipsychotics before clozapine was 3.5 ± 1.4 (range 1-10). Improvement with clozapine was documented as significant (31.7%), moderate (32.9%), minimal (12.2%), no improvement (2.4%), and not described (20.7%).
In this cohort, 95% of pediatric patients admitted with or started on clozapine during an acute psychiatric hospitalization were discharged on the medication. The high incidence of adverse events should reinforce to clinicians the need for vigilant monitoring. Pediatric guidelines recommend clozapine for refractory schizophrenia but stress the critical need to ensure an accurate diagnosis. Limited data exist for the use of clozapine in pediatric patients with other diagnoses.
氯氮平是治疗难治性精神分裂症的首选药物。虽然儿科使用氯氮平并无禁忌,但描述其临床应用的文献有限。本研究的主要目的是通过描述该药物已记录的安全性和临床益处,评估氯氮平在儿童和青少年人群中的使用情况。
在美国和澳大利亚各研究点开展的一项多中心回顾性研究,纳入了入住精神科病房且至少接受过一剂氯氮平治疗的儿童和青少年。收集了与人口统计学、患者病史、既往治疗、氯氮平及不良事件相关的信息。
本研究纳入了来自8个研究点的82例患者。患者大多未曾使用过氯氮平(76.8%),且多数出院诊断为原发性精神障碍(61%)或双相情感障碍(25.6%)。住院期间,有4例因严重中性粒细胞减少、肠梗阻、需要明确诊断以及显著的精神运动迟缓而停用氯氮平。其余患者(n = 78)出院时氯氮平的平均剂量为218.1 ± 142.2 mg。镇静(26.8%)和流涎(17.1%)是记录中最常见的不良事件。氯氮平治疗前,患者之前尝试使用抗精神病药物的平均次数为3.5 ± 1.4次(范围为1 - 10次)。记录显示使用氯氮平后改善显著的患者占31.7%,中度改善的占32.9%,轻度改善的占12.2%,无改善的占2.4%,未描述改善情况的占20.7%。
在该队列中,95%在急性精神科住院期间接受氯氮平治疗或开始使用氯氮平的儿科患者出院时仍在服用该药物。不良事件的高发生率应促使临床医生加强警惕性监测。儿科指南推荐氯氮平用于难治性精神分裂症,但强调确保准确诊断的迫切需要。关于氯氮平在患有其他诊断的儿科患者中的使用数据有限。